Response by Bonde and Martinussen to Letter Regarding Article, "Rivaroxaban Versus Apixaban for Stroke Prevention in Atrial Fibrillation: An Instrumental Variable Analysis of a Nationwide Cohort"

Circ Cardiovasc Qual Outcomes. 2020 Aug;13(8):e007003. doi: 10.1161/CIRCOUTCOMES.120.007003. Epub 2020 Aug 19.

Authors

Anders Nissen Bonde¹, Torben Martinussen²

Affiliations

¹ Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark (A.N.B.).
² Department of Public Health, Section of Biostatistics, University of Copenhagen, Denmark (T.M.).

PMID: 32813563
DOI: 10.1161/CIRCOUTCOMES.120.007003

No abstract available

Publication types

Letter
Comment

MeSH terms

Atrial Fibrillation* / complications
Atrial Fibrillation* / diagnosis
Atrial Fibrillation* / drug therapy
Humans
Pyrazoles
Pyridones / adverse effects
Rivaroxaban / adverse effects
Stroke* / diagnosis
Stroke* / epidemiology
Stroke* / etiology

Substances

Pyrazoles
Pyridones
apixaban
Rivaroxaban